Skip to main content
. 2015 Jun 24;10(6):e0130700. doi: 10.1371/journal.pone.0130700

Fig 3. PLSR models performance in predicting Erlotinib-treated patient survival in the BATTLE trial.

Fig 3

A. Erlotinib model predicting Erlotinib treated patients; B. Sorafenib model predicting Sorafenib treated patients; C. Erlotinib model predicting Sorafenib treated patients; and D. Sorafenib model predicting Erlotinib treated patients. TP: true positive; FP: false positive; TN: true negative; FN: false negative; PPV: positive predictive value.